…Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C.
…SEATTLE, Aug 11, 2014 (BUSINESS WIRE) — TapImmune, Inc. (the “Company”), (otcqb:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share.
In addition, the Company will issue to the investor warrants to purchase up to 1,886,793 shares of common stock.
…SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide vaccine in patients with advanced stage epithelial ovarian cancer has started at the Mayo Clinic, Rochester, MN. The folate receptor alpha peptides being used in this study are the same ones that are being used in a current Phase I study in breast and ovarian cancer.
…International Arbitration Tribunal Finds in Favor of TapImmune Inc., and Awards the Company $196,204 in Damages
TapImmune Inc. (TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.
The International Center for Dispute Resolution International Arbitration Tribunal has found that Mr. Gardner made numerous false representations, did not fully provide the services he was hired to perform and did not intend to perform them at the time he was hired.
TapImmune Inc. (TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company’s scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, a nonprofit biomedical research institute in Port St.
…New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System
TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance the visibility of cancer or infected cells to a patient’s immune system, a critical aspect of an effective vaccine.
TapImmune Inc. (TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer.
Folate receptor alpha is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic.
…Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.
The conference is taking place at the Ritz Carlton Hotel in Dana Point, California March 9-12, 2014 and is one of the largest of its kind, attended by numerous emerging growth companies and their investors.
…Results Meet Management’s Highest Expectations
TapImmune Inc. (TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes.
TapImmune Inc. (TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.
Over the past few years TapImmune has developed a strong scientific and clinical position in immunotherapy but has lacked the financial resources to fully leverage it. To address this, we now announce the completion of a corporate restructuring to attract the financial backing of some of the most respected names in life science to aid us in executing our product development plans and to provide fuel for our growth.